Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 2/20 | 0.65 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.63 |
| ▸ | KISS1R | Q969F8 | 12/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11321166 | 0.98 | GNRHR (0.63) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL29425245 | 0.97 | GNRHR (0.62) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL34464914 | 0.95 | GNRHR (0.60) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL30387715 | 0.94 | KISS1R (0.62) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL29942618 | 0.93 | C5AR1 (0.64) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL30271248 | 0.93 | C5AR1 (0.64) | GNRHRABCC2KISS1RPTGS1C5AR1 | |
| SCHEMBL11593491 | 0.93 | KISS1R (0.56) | GNRHRABCC2KISS1RPTGS1CXCR4 | |
| SCHEMBL29942444 | 0.93 | KISS1R (0.56) | GNRHRABCC2KISS1RPTGS1CXCR4 | |
| Hydrochloric Acid SCHEMBL11592749 | 0.92 | KISS1R (0.55) | GNRHRABCC2KISS1RPTGS1CXCR4 | |
| SCHEMBL30567819 | 0.91 | KISS1R (0.64) | GNRHRABCC2KISS1RPTGS1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | GNRHR 289/4885ABCC2 440/4885KISS1R 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.